ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2851 • 2014 ACR/ARHP Annual Meeting

    The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis

    Christopher Mecoli1, Fan Wang2, Christopher Pappas3, Peter C. Grayson4, David Cuthbertson5, Simon Carette6, Christian Pagnoux6, Gary S. Hoffman7, Nader A. Khalidi8, Curry L. Koening9, Carol A. Langford10, Carol McAlear11, Paul A. Monach12, Larry W. Moreland13, Philip Seo14, Ulrich Specks15, Steven R. Ytterberg16, Rui Feng17, Gregory Hageman3 and Peter A. Merkel1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, OK, 3University of Utah School of Medicine, Salt Lake City, UT, 4NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 5Department of Biostatistics, University of South Florida, Tampa, FL, 6Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 7Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, 9Division of Rheumatology, University of Utah, Salt Lake City, UT, 10Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 11Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 12Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, 13Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 14Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 15Frederichs Dr NW, Mayo Clinic, Rochester, MN, 16Division of Rheumatology, Mayo Clinic, Rochester, MN, 17Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Patients with age-related macular degeneration (AMD), a leading cause of irreversible blindness, have a 10-fold increased prevalence of abdominal aortic aneurysms. Single nucleotide polymorphisms…
  • Abstract Number: 2764 • 2014 ACR/ARHP Annual Meeting

    S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes

    Juan J. Maya1, Vikram Puvenna2,3,4, Chanda Brennan2,3,5, Seby John6, Ken Uchino7, Leonard H. Calabrese8, Damir Janigro2,4,9,10 and Rula Hajj-Ali11, 1Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 2Cerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 3Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 4Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 5Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 69500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, 7Neurology, Cleveland Clinic Foundation, Cleveland, OH, 8Cleveland Clinic Foundation, Cleveland, OH, 9Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 10Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 11Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Reversible Cerebral Vasoconstriction Syndromes (RCVS) are a group of disorders characterized by acute onset of recurrent thunderclap headaches with or without neurologic deficits. Radiologically,…
  • Abstract Number: 1788 • 2014 ACR/ARHP Annual Meeting

    Association of HLA-B*41 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status

    Fernanda Genre1, Raquel López-Mejías1, Belén Sevilla Pérez2, Santos Castañeda3, Norberto Ortego-Centeno2, Javier Llorca4, Begoña Ubilla1, Trinitario Pina Murcia1, Vanesa Calvo-Río5, Ana Márquez6, Luis Sala-Icardo7, Jose A. Miranda-Filloy8, Marta Conde-Jaldón9, Lourdes Ortiz-Fernández9, Juan María Blanco-Madrigal10, Eva Galindez-Agirregoikoa10, Francisca González Escribano9, Javier Martin11, Ricardo Blanco12 and MA González-Gay1, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, 3Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 4Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 5Av. Cardenal Herrera Oria s/n - Lab. 201, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 6Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 7Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 8Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, 9Immunology department, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 10Rheumatology Department. Basurto University Hospital, Bilbao, Spain, 11Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 12Hospital Marques de Valdecilla, Santander, Spain

    Background/Purpose: Henoch-Schönlein purpura (HSP), the most common type of primary small-sized blood vessel leukocytoclastic vasculitis, is characterized by infiltration of the small blood vessels with…
  • Abstract Number: 1780 • 2014 ACR/ARHP Annual Meeting

    Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis

    Joanna Ueng1, Katerina Pavenski2 and Laurence Rubin3, 1Rheumatology/Medicine, University of Toronto, Toronto, ON, Canada, 2Transfusion Medicine, St. Michael's Hospital, Toronto, ON, Canada, 3Rheumatology, St. Michael Hospital, Toronto, ON, Canada

    Background/Purpose Microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and Churg-Strauss Syndrome (CSS) are syndromes known as ANCA-associated vasculitis (AAV).  In addition to immunosuppressive therapy, plasma…
  • Abstract Number: 2787 • 2013 ACR/ARHP Annual Meeting

    The Effect Of Smoking On The Clinical Expression Of ANCA-Associated Vasculitis

    Neil Basu1, Aladdin Mohammad2, Richard A. Watts3, Paul Gatenby4, Luis F. Flores-Suarez5 and Alfred Mahr6, 1Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Department of Rheumatology, Skåne University Hospital, Lund, Sweden, 3Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, 4ANU Medical School, The Canberra Hospital, Canberra, Australia, 5Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 6Department of Internal Medicine, Hospital Saint-Louis, Paris, France

    Background/Purpose: It is well recognized that smoking has immuno-modulatory effects in several chronic inflammatory disorders. For ANCA-associated vasculitis (AAV), which includes granulomatosis with polyangiitis (GPA)…
  • Abstract Number: 2633 • 2013 ACR/ARHP Annual Meeting

    Clinical Spectrum Of Cutaneous Vasculitis

    Javier Loricera1, Vanesa Calvo-Río1, Francisco Ortiz-Sanjuan2, Héctor Fernández-Llaca3, Marcos A. González-López4, Lino Álvarez5, M. Carmen González-Vela6, Domingo González-Lamuño7, Cristina Mata2, Javier Rueda-Gotor8, Víctor M. Martínez-Taboada9, Miguel Angel González-Gay2 and Ricardo Blanco10, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 3Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 4Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 6Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 7Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, 8Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 9Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, 10Hospital Marques de Valdecilla, Santander, Spain

    Background/Purpose: Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is…
  • Abstract Number: 1657 • 2013 ACR/ARHP Annual Meeting

    Enothelin-1 Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome

    Tariq Hammad1, Leonard H. Calabrese2, Ken Uchino3, Seby John3, Mark Stillman4, Stewart Tepper4, Colin O'Rourke5, Allison Janocha1, Serpil Erzurum1 and Rula Hajj-Ali4, 1Cleveland Clinic, Cleveland, OH, 2Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 3Neurology, Cleveland Clinic Foundation, Cleveland, OH, 4Cleveland Clinic Foundation, Cleveland, OH, 5Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

    Background/Purpose:    Cerebral vasoconstriction    is thought to be the underlying pathogenetic mechanism   of Reversible Cerebral Vasoconstriction Syndromes (RCVS). However, mediators of the syndrome at molecular levels…
  • Abstract Number: 1660 • 2013 ACR/ARHP Annual Meeting

    Primary  Central  Nervous  System  Vasculitis: Treatment and Course

    Carlo Salvarani1, Robert D. Brown Jr.2, Teresa J. H. Christianson2, John Huston III2, Kenneth Calamia3, Caterina Giannini2 and Gene G. Hunder4, 1Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Jacksonville, FL, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: To determine the response to therapy and long-term outcome of PCNSV we reviewed all cases of PCNSV seen over a 29-year period.    Methods:…
  • Abstract Number: 854 • 2013 ACR/ARHP Annual Meeting

    Aortic Wall Thickness In Patients Without Aortitis:  a Computed Tomography-Based Study Of 100 Patients

    Afif Nakhleh1, Irina Rukhkyan2, Vladimir Wolfson3, Itzhak A. Rosner4, Majed Odeh4 and Gleb Slobodin5, 1Internal Medicine, Bnai Zion Medical Center, Haifa, Israel, 2Rehabilition, Bnai Zion Medical Center, Haifa, Israel, 3Radiology, Bnai Zion Medical Center, Haifa, Israel, 4Bnai Zion Medical Center, Haifa, Israel, 5Rheumatology, Bnai Zion Medical Center, Haifa, Israel

    Background/Purpose: Thickening of the aortic wall, probably the earliest CT sign of aortitis, is frequently missed as there are no accepted criteria for normal aortic…
  • Abstract Number: 2566 • 2012 ACR/ARHP Annual Meeting

    Aβ-Related Angiitis: Comparison with Patients with Amyloid Cerebral Angiopathy without Inflammation

    Carlo Salvarani1, Caterina Giannini2, Robert D. Brown Jr.2, Teresa J. H. Christianson2 and Gene G. Hunder3, 1Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 2Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose:  Coexistence of sporadic cerebral amyloid angiopathy (CAA) and primary central nervous system vasculitis (PCNSV) has been reported, particularly in patients with granulomatous vasculitis. This…
  • Abstract Number: 2388 • 2012 ACR/ARHP Annual Meeting

    Urticarial Vasculitis: Clinical Study

    Javier Loricera1, Vanesa Calvo-Rio2, Francisco Ortiz Sanjuan2, Marcos Antonio Gonzalez-Lopez3, Hector Fernandez-Llaca3, Javier Rueda-Gotor2, Carmen Gonzalez-Vela4, Cristina Mata-Arnaiz5, Jose Luis Peña-Sagredo2, Miguel A. Gonzalez-Gay2 and Ricardo Blanco2, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 3Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 4Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5Rheumatology, Hospital Laredo, Santander, Spain

    Background/Purpose: Urticarial vasculitis is an infrecuent subset of vasculitis described by McDuffy et al, in 1973, characterized clinically by urticarial skin lesions of more than…
  • Abstract Number: 2391 • 2012 ACR/ARHP Annual Meeting

    New Disease Manifestations After Diagnosis in Six Types of Vasculitis

    Peter C. Grayson1, David Cuthbertson2, Simon Carette3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Kathleen Maksimowicz-McKinnon8, Paul A. Monach9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg12 and Peter A. Merkel13, 1Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, 2Department of Biostatistics, University of South Florida, Tampa, FL, 3Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, 4Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 5Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 6Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, 7Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 8Rheumatology, University of Pittsburgh, Pittsburgh, PA, 9Rheumatology, Boston University, Boston, MA, 10Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Rheumatology Division, Mayo Clinic, Rochester, MN, 13University of Pennsylvania, Philadelphia, PA

       Background/Purpose: The proportion of patients who experience new manifestations of vasculitis after diagnosis is unknown.  Our objectives were to quantify the occurrence of new…
  • Abstract Number: 2365 • 2012 ACR/ARHP Annual Meeting

    Asymptomatic Myocardial Ischemic Disease in Takayasu’s Arteritis

    Chloe Comarmond1, Odile Dessault2, jean-Yves Devaux2, Nathalie Costedoat-Chalumeau3, Mathieu Resche Rigon4, Richard Isnard5, Fabien Koskas6, Patrice Cacoub Sr.7 and David Saadoun8, 1Internal Medicine, Hôpital Pitié Salpétrière, Paris, France, 2Department of Nuclear Medicine, Groupe Hospitalier Saint-Antoine, Paris, France, 3Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 4Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 5Cardiology, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75651 Paris Cedex 13, Paris, France, Paris, France, 6Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 7Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, 8DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France

    Background/Purpose: Cardiac involvement in Takayasu's arteritis (TA) is a leading cause of death. Previous studies reported a high incidence of myocardial involvement using exercise thallium-201…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology